ImmunoGen Inc (IMGN.O) Quote| Reuters.com
Edition:
United States

ImmunoGen Inc (IMGN.O)

IMGN.O on Nasdaq

3.13USD
24 Jun 2016
Change (% chg)

$-0.19 (-5.72%)
Prev Close
$3.32
Open
$3.19
Day's High
$3.28
Day's Low
$3.12
Volume
1,524,752
Avg. Vol
1,725,989
52-wk High
$19.43
52-wk Low
$3.12

IMGN.O

Chart for IMGN.O

About

ImmunoGen, Inc. (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Company's clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which is a type of medicine that uses a monoclonal antibody to deliver a therapeutic agent to... (more)

Overall

Beta: 2.00
Market Cap(Mil.): $272.55
Shares Outstanding(Mil.): 87.08
Dividend: --
Yield (%): --

Financials

  IMGN.O Industry Sector
P/E (TTM): -- 38.82 34.11
EPS (TTM): -1.49 -- --
ROI: -88.15 -5.72 14.23
ROE: -1,396.55 -4.83 15.46

BRIEF-ImmunoGen announces pricing of $100 mln offering of Senior Notes

* Sale of notes is expected to result in $96.7 million net proceeds to Immunogen

Jun 15 2016

BRIEF-Immunogen announces proposed $100 mln offering of convertible senior notes

* Immunogen announces proposed $100 million offering of convertible senior notes due 2021

Jun 13 2016

BRIEF-ImmunoGen reports positive early-stage data on ovarian cancer drug

* Reports efficacy and safety data from a 46 patient cohort of mirvetuximab soravtansine in fr-positive ovarian cancer

May 18 2016

BRIEF-ImmunoGen Inc Q3 loss per share $0.37

* Immunogen Inc reports third quarter fiscal year 2016 financial results and provides corporate update

Apr 29 2016

BRIEF-Immunogen appoints Mark Enyedy to newly-expanded board

* Board has voted to expand size of board from nine to ten members, and appointed Mark Enyedy to fill newly-created vacancy - SEC filing Source text for Eikon: [(http://1.usa.gov/1SHhbkP )] Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Apr 26 2016

BRIEF-ImmunoGen appoints Mark Enyedy as president and CEO

* Immunogen appoints Mark Enyedy as president and chief executive officer

Apr 26 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$104.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.